These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 33812260)

  • 1. The effect of tocilizumab on COVID-19 patient mortality: A systematic review and meta-analysis of randomized controlled trials.
    Lin WT; Hung SH; Lai CC; Wang CY; Chen CH
    Int Immunopharmacol; 2021 Jul; 96():107602. PubMed ID: 33812260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tocilizumab in addition to standard of care in the management of COVID-19: a meta-analysis of RCTs.
    Mutua V; Henry BM; Csefalvay CV; Cheruiyot I; Vikse J; Lippi G; Bundi B; Mong'are N
    Acta Biomed; 2022 Mar; 93(1):e2022014. PubMed ID: 35315395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update.
    Tleyjeh IM; Kashour Z; Riaz M; Hassett L; Veiga VC; Kashour T
    Clin Microbiol Infect; 2021 Aug; 27(8):1076-1082. PubMed ID: 33915284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis.
    Tleyjeh IM; Kashour Z; Damlaj M; Riaz M; Tlayjeh H; Altannir M; Altannir Y; Al-Tannir M; Tleyjeh R; Hassett L; Kashour T
    Clin Microbiol Infect; 2021 Feb; 27(2):215-227. PubMed ID: 33161150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis.
    Kyriakopoulos C; Ntritsos G; Gogali A; Milionis H; Evangelou E; Kostikas K
    Respirology; 2021 Nov; 26(11):1027-1040. PubMed ID: 34605114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic Review and Meta-Analysis of Tocilizumab Therapy versus Standard of Care in over 15,000 COVID-19 Pneumonia Patients during the First Eight Months of the Pandemic.
    Mahroum N; Watad A; Bridgewood C; Mansour M; Nasr A; Hussein A; Khamisy-Farah R; Farah R; Gendelman O; Lidar M; Shoenfeld Y; Amital H; Kong JD; Wu J; Bragazzi NL; McGonagle D
    Int J Environ Res Public Health; 2021 Aug; 18(17):. PubMed ID: 34501738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of tocilizumab in the treatment of hospitalized adults COVID-19: A systematic review and meta-analysis.
    Zhang J; Chen C; Yang Y; Yang J
    Medicine (Baltimore); 2022 Mar; 101(9):e28967. PubMed ID: 35244063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between tocilizumab treatment and clinical outcomes of COVID-19 patients: a systematic review and meta-analysis.
    Peng J; She X; Mei H; Zheng H; Fu M; Liang G; Wang Q; Liu W
    Aging (Albany NY); 2022 Jan; 14(2):557-571. PubMed ID: 35038318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials.
    Snow TAC; Saleem N; Ambler G; Nastouli E; Singer M; Arulkumaran N
    Intensive Care Med; 2021 Jun; 47(6):641-652. PubMed ID: 34019122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab in patients hospitalized with COVID-19 pneumonia: systematic review and meta-analysis of randomized controlled trials.
    Gupta S; Padappayil RP; Bansal A; Daouk S; Brown B
    J Investig Med; 2022 Jan; 70(1):55-60. PubMed ID: 34561232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tocilizumab for severe COVID-19: a systematic review and meta-analysis.
    Lan SH; Lai CC; Huang HT; Chang SP; Lu LC; Hsueh PR
    Int J Antimicrob Agents; 2020 Sep; 56(3):106103. PubMed ID: 32712333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab in the treatment of COVID-19-a meta-analysis.
    Avni T; Leibovici L; Cohen I; Atamna A; Guz D; Paul M; Gafter-Gvili A; Yahav D
    QJM; 2021 Nov; 114(8):577-586. PubMed ID: 34010403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis.
    Rezaei S; Fatemi B; Karimi Majd Z; Minaei H; Peikanpour M; Anjidani N; Taheri A; Dastan F; Mosaed R
    Expert Rev Clin Immunol; 2021 May; 17(5):499-511. PubMed ID: 33823733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID-19; a systematic review and meta-analysis of randomized clinical trials.
    Vela D; Vela-Gaxha Z; Rexhepi M; Olloni R; Hyseni V; Nallbani R
    Br J Clin Pharmacol; 2022 May; 88(5):1955-1963. PubMed ID: 34713921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials.
    Kow CS; Hasan SS
    Eur J Clin Pharmacol; 2021 Aug; 77(8):1089-1094. PubMed ID: 33532896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocilizumab and COVID-19: a meta-analysis of 2120 patients with severe disease and implications for clinical trial methodologies.
    Sarfraz A; Sarfraz Z; Sarfraz M; Aftab H; Pervaiz Z
    Turk J Med Sci; 2021 Jun; 51(3):890-897. PubMed ID: 33244947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of subcutaneous vs. intravenous tocilizumab in patients with severe COVID-19: a systematic review.
    Li Y; Li X; Zheng X
    Eur J Clin Pharmacol; 2024 Oct; 80(10):1523-1530. PubMed ID: 38926166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.
    Salvarani C; Dolci G; Massari M; Merlo DF; Cavuto S; Savoldi L; Bruzzi P; Boni F; Braglia L; Turrà C; Ballerini PF; Sciascia R; Zammarchi L; Para O; Scotton PG; Inojosa WO; Ravagnani V; Salerno ND; Sainaghi PP; Brignone A; Codeluppi M; Teopompi E; Milesi M; Bertomoro P; Claudio N; Salio M; Falcone M; Cenderello G; Donghi L; Del Bono V; Colombelli PL; Angheben A; Passaro A; Secondo G; Pascale R; Piazza I; Facciolongo N; Costantini M;
    JAMA Intern Med; 2021 Jan; 181(1):24-31. PubMed ID: 33080005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.
    Salama C; Han J; Yau L; Reiss WG; Kramer B; Neidhart JD; Criner GJ; Kaplan-Lewis E; Baden R; Pandit L; Cameron ML; Garcia-Diaz J; Chávez V; Mekebeb-Reuter M; Lima de Menezes F; Shah R; González-Lara MF; Assman B; Freedman J; Mohan SV
    N Engl J Med; 2021 Jan; 384(1):20-30. PubMed ID: 33332779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.